SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 07:54:17 2024-06-18 EDT | ||
| 3.2 EUR | -0.31% |
|
| Current month | +1.26% | ||
| 1 month | +11.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-18 | 3.2 | -0.31% |
| 24-06-17 | 3.21 | +1.58% |
| 24-06-14 | 3.16 | +0.32% |
| 24-06-13 | 3.15 | +4.30% |
| 24-06-12 | 3.02 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 18, 2024 at 07:54 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU3G5Q |
| ISIN | DE000VU3G5Q4 |
| Date issued | 2023-02-10 |
| Strike | 75.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.26 € |
|---|---|
| Lowest since issue | 0.32 € |
| Spread | 0.01 € |
| Spread % | 0.31% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.97
USD
Average target price
53.19
USD
Spread / Average Target
+29.84%
- Stock Market
- Certificates
- Certificat
